Development of a Topical Polymeric Mucoadhesive Ocular Delivery System for Azithromycin

被引:40
作者
Bowman, Lyle M. [1 ]
Si, Erwin [2 ]
Pang, Joseph [3 ]
Archibald, Roy [4 ]
Friedlaender, Mitchell [5 ]
机构
[1] InSite Vis, Dev & Operat, Alameda, CA 94501 USA
[2] InSite Vis, Preclin Res, Alameda, CA 94501 USA
[3] InSite Vis, Analyt Chem, Alameda, CA 94501 USA
[4] InSite Vis, Mfg, Alameda, CA 94501 USA
[5] Scripps Res Inst, La Jolla, CA USA
关键词
EYE DROPS; BACTERIAL CONJUNCTIVITIS; PHARMACOKINETICS; TOBRAMYCIN; 0.3-PERCENT; SERUM; TRIAL;
D O I
10.1089/jop.2008.0066
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Azithromycin is an azalide class of antibiotic with pharmacodynamics that have made it a valuable agent in the treatment of soft tissue infections. In ophthalmology, oral administration of azithromycin has been proven effective for the treatment of trachoma. However, topical formulations of azithromycin to treat ocular surface infections have been challenging to develop because of the drug's hydrophobicity and instability in aqueous solutions at pH levels that are comfortable in the eye. The design of a polycarbophil polymer-based delivery system for a topical formulation of azithromycin was evaluated for its ability to provide drug stability, comfort, and increased retention of the formulation in the eye. Methods: Formulations of 0.5% and 1.0% azithromycin were created in polycarbophil, a lightly cross-linked polyacrylic acid polymer that was adjusted to a viscosity, pH, and osmolality that are suitable for dispensing in the eye. Results: The polycarbophil-based ophthalmic delivery system, DuraSite (InSite Vision, Alameda, CA), helps solubilize azithromycin and retard its degradation in aqueous solution. The formulation was stable at room temperature as well as 5 degrees C. Upon administration of a single drop of 1% azithromycin in DuraSite ophthalmic solution in rabbits' eyes, tear concentrations of azithromycin ranged from 87 to 288 mu g/g and high concentrations were sustained for over a 24-h period. Conclusions: Azithromycin can be developed as an eyedrop in an aqueous ocular delivery system for the treatment of ocular surface infections. The ocular delivery system, DuraSite solubilizes azithromycin at a high concentration in an aqueous solution and protects it from degradation during manufacture and storage. The development of azithromycin in this delivery system enhances the antibiotic's usefulness in ophthalmology for the topical treatment of ocular surface bacterial infections and lid margin diseases.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 28 条
  • [11] KIEWEG SL, 2005, J PHARM SCI, V96, P835
  • [12] Corneal pharmacokinetics of topically applied azithromycin and clarithromycin
    Kuehne, JJ
    Yu, ALT
    Holland, GN
    Ramaswamy, A
    Taban, R
    Mondino, BJ
    Fei, Y
    Rayner, SA
    Giese, MJ
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 138 (04) : 547 - 553
  • [13] Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen
    Liu, Ping
    Allaudeen, Hameed
    Chandra, Richa
    Phillips, Kem
    Jungnik, Arvid
    Breen, Jeanne D.
    Sharma, Amarnath
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (01) : 103 - 109
  • [14] Safety, toleration, and pharmacokinetics of intravenous azithromycin
    Luke, DR
    Foulds, G
    Cohen, SF
    Levy, B
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) : 2577 - 2581
  • [15] A comparative bioavailability study of three conventional eye drops versus a single lyophilisate
    Lux, A
    Maier, S
    Dinslage, S
    Süverkrüp, R
    Diestelhorst, M
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2003, 87 (04) : 436 - 440
  • [16] McHugh R C, 2004, J Dermatolog Treat, V15, P295, DOI 10.1080/09546630410033808
  • [17] UPTAKE OF AZITHROMYCIN BY HUMAN MONOCYTES AND ENHANCED INTRACELLULAR ANTIBACTERIAL ACTIVITY AGAINST STAPHYLOCOCCUS-AUREUS
    MEYER, AP
    BRILBAZUIN, C
    MATTIE, H
    VANDENBROEK, PJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) : 2318 - 2322
  • [18] *NDA, 50733S005 NDA
  • [19] PARK H, 1985, Journal of Controlled Release, V2, P47, DOI 10.1016/0168-3659(85)90032-X
  • [20] *PFIZ PFIZ LABS DI, 2007, ZITHR TABL OR SUSP F